SCHEMBL6258308

SCHEMBL6258308

COc1ccc(OC)c(COS(C)(=O)=O)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.60
HSD17B10 Q99714 1/20 0.53
ADRA1A P35348 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
HTR2A P28223 1/20 0.49
ALDH1A1 P00352 1/20 0.47
AOC3 Q16853 1/20 0.46
GAA P10253 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MTNR1A P48039 1/20 0.44
MTNR1B P49286 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8688214 0.87 APLNR (0.53) IDO1HSD17B10ALDH1A1GAACA12
SCHEMBL1640006 0.86 IDO1 (0.45) IDO1HSD17B10ADRA1ATAAR1GAA
SCHEMBL27632987 0.82 MAPT (0.46) IDO1ADRA1ATAAR1ALDH1A1GAA
SCHEMBL15414420 0.82 IDO1 (0.39) IDO1HSD17B10ALDH1A1GAA
SCHEMBL15415062 0.82 TRPV4 (0.50) ALDH1A1CA1CA2CA9L3MBTL1
SCHEMBL6464409 0.82 CHRM2 (0.47) IDO1ADRA1ATAAR1MTNR1B
SCHEMBL15413756 0.82 LMNA (0.49) HSD17B10ALDH1A1GAAL3MBTL1
SCHEMBL27772408 0.81 HSD17B10 (0.55) IDO1HSD17B10ADRA1ATAAR1HTR2A
SCHEMBL6435463 0.80 ALDH1A1 (0.41) IDO1ALDH1A1GAACA12CA2
SCHEMBL15414346 0.80 ALDH1A1 (0.43) IDO1ALDH1A1CA1CA2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297262-A1 PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES COLBY PHARMACEUTICAL COMPANY (US) 2010-11-25 US disclosed
WO-2005065074-A2 PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-07-21 WO disclosed
US-5811439-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS SENGA PHARMACEUTICAL LABORATORY INC. (JP) 1998-09-22 US disclosed
CN-1167111-A Thiazolidinedione derivatives, method for preparing derivatives and pharmaceutical compositions containing same SENGA PHARMACEUTICAL LAB INC (JP) 1997-12-10 CN disclosed
EP-0780389-A1 Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them TOBISHI PHARMACEUTICAL CO., LTD. (JP) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297262-A1 PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES MPO, HMOX1, LPO IDO1 838/4885HSD17B10 2720/4885ADRA1A 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.